This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer. 2001;1:181–93.
Schlenk RF, Frohling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia. 2004;18:1798–803.
Milligan DW, Wheatley K, Littlewood T, Craig JI, Burnett AK, Group NHOCS. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood. 2006;107:4614–22.
Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT, Bruserud O. In vivo biological effects of ATRA in the treatment of AML. Expert Opin Investig drugs. 2008;17:1623–33.
McKeown MR, Corces MR, Eaton ML, Fiore C, Lee E, Lopez JT, et al. Super-enhancer analysis defines novel epigenomic subtypes of non-APL AML including an RARalpha dependency targetable by SY-1425, a potent and selective RARalpha agonist. Cancer Discov. 2017;7:1136–53. https://doi.org/10.1158/2159-8290.CD-17-0399.
Su M, Alonso S, Jones JW, Yu J, Kane MA, Jones RJ, et al. All-trans retinoic acid activity in acute myeloid leukemia: role of cytochrome P450 enzyme expression by the microenvironment. PLoS ONE. 2015;10:e0127790.
Warrell RP Jr., Frankel SR, Miller WH Jr., Scheinberg DA, Itri LM, Hittelman WN, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991;324:1385–93.
Tsimberidou AM, Tirado-Gomez M, Andreeff M, O’Brien S, Kantarjian H, Keating M, et al. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma. 2006;47:1062–8.
Ghiaur G, Yegnasubramanian S, Perkins B, Gucwa JL, Gerber JM, Jones RJ. Regulation of human hematopoietic stem cell self-renewal by the microenvironment’s control of retinoic acid signaling. Proc Natl Acad Sci USA. 2013;110:16121–6.
Delescluse C, Cavey MT, Martin B, Bernard BA, Reichert U, Maignan J, et al. Selective high affinity retinoic acid receptor alpha or beta-gamma ligands. Mol Pharmacol. 1991;40:556–62.
Szondy Z, Reichert U, Bernardon JM, Michel S, Toth R, Karaszi E, et al. Inhibition of activation-induced apoptosis of thymocytes by all-trans- and 9-cis-retinoic acid is mediated via retinoic acid receptor alpha. Biochemical J. 1998;331:767–74.
Owusu SA, Ross AC. Retinoid homeostatic gene expression in liver, lung and kidney: ontogeny and response to vitamin A-retinoic acid (VARA) supplementation from birth to adult age. PLoS ONE. 2016;11:e0145924.
Topletz AR, Thatcher JE, Zelter A, Lutz JD, Tay S, Nelson WL, et al. Comparison of the function and expression of CYP26A1 and CYP26B1, the two retinoic acid hydroxylases. Biochemical Pharmacol. 2012;83:149–63.
Alonso S, Hernandez D, Chang YT, Gocke CB, McCray M, Varadhan R, et al. Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance. J Clin Investig. 2016;126:4460–8.
Alonso S, Jones RJ, Ghiaur G. Retinoic acid, CYP26, and drug resistance in the stem cell niche. Exp Hematol. 2017;54:17–25.
Acknowledgements
The project was by enlarged funded by K08 HL127269 (GG), R03 HL145226 (GG), P01CA225618 (BDS, RJJ, GG), and LLS TRP 14086277 (RJJ). LP was covered by T32HL007525 (PI- Robert Brodsky). Quantification of the IRX195183 was performed by the Analytical Pharmacology Core of Johns Hopkins covered by NIH grants P30 CA006973, UL1 TR 001079, and S10RR026824.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
SA, RC, RJJ, and GG are authors on a patent application for the use of IRX195183.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Hernandez, D., Palau, L., Norsworthy, K. et al. Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids. Leukemia 34, 3077–3081 (2020). https://doi.org/10.1038/s41375-020-0790-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-020-0790-4